Skip to main content

Table 3 OS and CSS in univariate and multivariate analyses

From: Association of chemotherapy with survival in stage II colon cancer patients who received radical surgery: a retrospective cohort study

Risk factors

OS

CSS

 

Univariate analyses

 

Multivariate analyses

Univariate analyses

 

Multivariate analyses

 

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

Age

 

0.000

   

0.000

  

  > 30

1

–

1

–

1

–

1

–

 30–39

1.71 (0.77–3.77)

–

1.75 (0.79–3.87)

0.166

1.39 (0.63–3.11)

–

1.37 (0.61–3.05)

0.447

 40–49

1.86 (0.88–3.96)

–

1.90 (0.89–4.05)

0.095

1.48 (0.69–3.15)

–

1.46 (0.68–3.11)

0.332

 50–59

2.55 (1.21–5.38)

–

2.44 (1.15–5.14)

0.020

1.94 (0.92–4.10)

–

1.76 (0.83–3.72)

0.139

 60–69

3.80 (1.80–7.99)

–

3.47 (1.65–7.32)

0.001

2.63 (1.24–5.54)

–

2.25 (1.06–4.75)

0.034

 70–79

6.63 (3.15–13.96)

–

5.57 (2.64–11.74)

0.000

4.07 (1.93–8.60)

–

3.11 (1.47–6.57)

0.003

  ≥ 80

12.97 (6.13–27.44)

–

9.96 (4.70–21.10)

0.000

7.58 (3.57–16.12)

–

5.14 (2.41–10.95)

0.000

Sex

 

0.024

   

0.902

  

 Female

1

–

1

–

1

–

–

–

 Male

1.10 (1.01–1.19)

–

1.32 (1.21–1.44)

0.000

1.01 (0.91–1.11)

–

–

–

Marital status

 

0.000

   

0.000

  

 Married

1

–

1

–

1

–

1

–

 Unmarrieda

1.57 (1.45–1.71)

–

1.33 (1.22–1.45)

0.000

1.58 (1.43–1.74)

–

1.27 (1.14–1.40)

0.000

Race

 

0.000

   

0.000

  

 White

1

–

1

–

1

–

1

–

 Black

1.29 (1.15–1.45)

–

1.41 (1.26–1.59)

0.000

1.41 (1.23–1.61)

–

1.47 (1.28–1.69)

0.000

 Other

0.73 (0.62–0.86)

–

0.77 (0.65–0.90)

0.001

0.86 (0.71–1.03)

–

0.88 (0.73–1.05)

0.161

Tumor site

 

0.048

   

0.000

  

 Right colonb

1

–

1

–

1

–

1

–

 Left colonc

1.09 (1.00–1.18)

–

1.14 (1.04–1.24)

0.003

1.21 (1.09–1.33)

–

1.25 (1.13–1.39)

0.000

Tumor size

 

0.001

   

0.016

  

 <5

1

–

1

–

1

–

1

–

  ≥ 5

1.15 (1.06–1.25)

–

1.03 (0.95–1.12)

0.494

1.13 (1.02–1.25)

–

0.99 (0.89–1.10)

0.864

Histology

 

0.000

   

0.001

  

 Adenocarcinoma

1

–

1

–

1

–

1

–

 Mucinous adenocarcinoma

1.14 (1.01–1.28)

–

0.97 (0.86–1.10)

0.668

1.14 (0.99–1.32)

–

1.00 (0.87–1.16)

0.964

 Signet ring cell carcinoma

2.09 (1.43–3.06)

–

1.34 (0.91–1.98)

0.138

2.20 (1.42–3.42)

–

1.45 (0.92–2.28)

0.105

Grade

 

0.000

   

0.020

  

 I

1

–

1

–

1

–

1

–

 II

1.00 (0.84–1.19)

–

1.06 (0.88–1.26)

0.553

0.98 (0.79–1.20)

–

1.04 (0.84–1.28)

0.750

 III

1.19 (0.98–1.45)

–

1.13 (0.93–1.38)

0.226

1.15 (0.92–1.45)

–

1.13 (0.90–1.44)

0.299

 IV

1.54 (1.14–2.08)

–

1.54 (1.14–2.09)

0.005

1.33 (0.92–1.92)

–

1.37 (0.95–1.99)

0.095

T stage

 

0.000

   

0.000

  

 T3

1

–

1

–

1

–

1

–

 T4

2.88 (2.65–3.13)

–

2.21 (2.02–2.41)

0.000

3.20 (2.90–3.53)

–

2.59 (2.33–2.87)

0.000

nLNd

 

0.000

   

0.000

  

 0

1

–

1

–

1

–

1

–

 1–11

0.52 (0.39–0.70)

–

0.56 (0.41–0.75)

0.000

0.41 (0.30–0.57)

–

0.48 (0.34–0.66)

0.000

  ≥ 12

0.31 (0.23–0.42)

–

0.38 (0.28–0.51)

0.000

0.25 (0.19–0.35)

–

0.33 (0.24–0.45)

0.000

CEAe

 

0.000

   

0.000

  

 Positive

1

–

1

–

1

–

1

–

 Negative

0.51 (0.47–0.55)

–

0.62 (0.57–0.67)

0.000

0.50 (0.45–0.55)

–

0.62 (0.56–0.69)

0.000

  1. aUnmarried, including single, widowed, divorced and separated;
  2. bRight colon, including the cecum, the ascending colon, the hepatic flexure and the transverse colon;
  3. cLeft colon, including the splenic flexure and the descending, sigmoid colons and rectosigmoid junction;
  4. dnLN number of lymph nodes; eCEA carcinoembryonic antigen
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us